Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors.
Clin Vaccine Immunol
; 21(6): 901-3, 2014 Jun.
Article
em En
| MEDLINE
| ID: mdl-24739980
ABSTRACT
Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Adenovirus dos Símios
/
Malária Falciparum
/
Vacinas Antimaláricas
/
Anticorpos Neutralizantes
/
Anticorpos Antivirais
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Animals
/
Child
/
Child, preschool
/
Humans
/
Infant
/
Middle aged
País como assunto:
Africa
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article